Notícia

Sekolah Eliminasi Malaria (Indonésia)

Senyawa baru memotong siklus hidup parasit malaria

Publicado em 07 outubro 2019

An international group of researchers has proven that a molecule called TCMDC-135051 can selectively inhibit a protein that is essential to the lifecycle ofPlasmodium falciparum, one of the parasites that causes malaria.

The results of the study, just published in the journalScience, pave the way for the development of a new antimalarial drug. Malaria kills nearly 500,000 people per year, and more than 200 million new cases of the disease are reported annually. One of the obstacles to eradication is the parasite’s emerging resistance to existing drugs.

The authors of the journal article include members of the University of Campinas’s Center for Medicinal Chemistry (CQMED-UNICAMP) in São Paulo State. CQMED is a unit of the Brazilian Agency for Industrial Research and Innovation (EMBRAPII) that specializes in biopharmaceuticals and pharmaceuticals. It is headed by Professor Paulo Arruda and supported by São Paulo Research Foundation – (FAPESP) through the foundation’s Research Partnership for Technological Innovation (PITE).

CQMED also belongs to the Structural Genomics Consortium (SGC), an international network that works to accelerate drug discovery through open-access research by scientists at universities, pharmaceutical companies and nonprofit organizations.

The article shows that the molecule TCMDC-135051, which is synthesized by global pharmaceutical giant GSK, acts specifically onP. falciparum‘s cyclin-dependent-like protein kinase PfCLK3 without affecting human proteins.

“Inhibition of PfCLK3 affects the parasite in both the asexual stage of its development, when it proliferates in human cells and causes symptoms, and the sexual stage, when it can be transmitted back to the vector insect, repeating the cycle by infecting other humans,” said Paulo Godoi, who conducted the research during a postdoctoral fellowship with CQMED.

Dev Sriranganadane, currently on a postdoctoral internship at CQMED, also took part in the study. The research was led by Andrew Tobin, Professor of Molecular Pharmacology at the University of Glasgow in the UK.

“The UNICAMP group played a key role in this project. They were able to say whether our drug might have other effects in addition to inhibiting PfCLK3. Without that information we couldn’t have proceeded with the study,” Tobin told.

Because parasites of the genusPlasmodiumare becoming increasingly resistant to existing antimalarials, novel compounds with the potential to be developed into drugs that prevent transmission and may even cure the disease are urgently needed.

“This PfCLK3 inhibitor is highly promising, as it can eliminate the parasite in all stages of its lifecycle,” Godoi said.

PfCLK3 controls the activity and production of other proteins required by the parasite to stay alive. By blocking these, TCMDC-135051 killsP. falciparumand not only prevents transmission but can also treat the disease in humans.

In a high-throughput screening assay to identify selective PfCLK3 inhibitors, the researchers analyzed 24,619 compounds and selected TCMDC-135051 because it showed the highest selectivity and potency in this regard.

The study also suggests that this molecule is effective against other species ofPlasmodium. According to Godoi, in vitro trials showed activity against CLK3 in cultured cells of P. viva, P. knowlesi andP. berghei.

“We also tested it in mice infected withP. berghei. The results of this in vivo trial showed that the parasite was eliminated from the bloodstream after five days of infection,” he said.

Brazilian contribution

To be considered safe, molecules that are drug candidates must not interfere with human proteins. Parasites of the genusPlasmodiumand humans have protein kinases, which orchestrate the activity of almost all cellular processes. The human kinase that most closely resemblesPlasmodium‘s PfCLK3 is PRPF4B. Tobin asked CQMED to confirm that TCMDC-135051 was safe because its members are among the few scientists who study the functions of PRPF4B.

“We had PRPF4B interact with the new molecule at different concentrations, and it proved unable to inhibit the human kinase even at the highest concentration,” Godoi said.

To guarantee the molecule’s safety so that drug development could proceed, the researchers had to show that it did not affect the activity of the proteins required by humans. “We focused on a protein that’s rarely been studied. The outcome was positive because it enabled this new study, which demonstrated major potential for the development of a new drug,” said Rafael Couñago, CQMED’s scientific coordinator.

To become a drug, however, this inhibitor will have to be submitted to more tests. “We need to improve the molecule’s safety even more. Then, it will be ready for trials in humans. That stage will take between three and five years,” Tobin said.

phys.org

Essa notícia também repercutiu nos veículos:
Folha.com Portal Exame Folha de S. Paulo UOL IstoÉ online IstoÉ Dinheiro online BOL Agência Brasil Estadão.com Cidade News Online Jornal Integração online Espaço Ecológico no Ar Central das Notícias Meridional FM Neatorama (EUA) Revista Amazônia O Estado (MS) online Conteúdo MS Jornal A Semana Esteta Panorama Farmacêutico Portal da Enfermagem NewsLab online APM- Associação Paulista de Medicina LabNetwork Jornal da Ciência online Blog Jornal da Mulher W Rádio Brasil Confap - Conselho Nacional das Fundações Estaduais de Amparo à Pesquisa 2A+ Farma Gazeta de Santarém online Panorama Farmacêutico Diga Bahia Acorda Cidade Gonzaga Patriota Brasil CT&I Portal Agora no RS The World News (Ucrânia/Brasil) O Povo online Mix Vale CGN Agência BR Jornal Tijucas A Tarde (BA) online Acesse Notícias Blog da Sociedade Brasileira de Parasitologia Região Noroeste Blog Belém! AssisCity Às Claras Bahia Recôncavo Blog Jair Sampaio Blog Ultimas Noticias Idest Expresso MT Portal OZK Portal da Feira Portal Bem Minas Portal Correio do Lago Poliarquia Painel Notícias A Tribuna (ES) online Iporã News Jornal do Lar Folha Vitória online LiberaPensado.com Voz do Bico Madeirão Cada Minuto Jornal do Commercio (PE) online O Documento online Jornal Ururau Repórter News Hoje em Dia online Correio Capixaba online Roraima 1 Bem Paraná online Conexão Tocantins Tarauacá Notícias Rondônia Vip Única Mania Portal F11 Agência Sertão Amazônia Brasil Rádio Web Aparecidanet Urgente News RedeTV (Porto Velho, RO) JP News AMRIGS - Associação Médica do Rio Grande do Sul Empresas & Negócios Jornal do Comércio (RS) O Liberal (PA) Correio do Brasil online Piauí Noticias Jornal do Ônibus (MT) Jornal Fatos & Notícias ID News InfoMidi Liberdades Jornal Expresso Carioca O Serrano online O Nortão online Futblog do Sorriso Portal Guará Edgar Lisboa Plantão News (MT) Camaçari 24 Horas Central de Notícias O Observador online Tribuna de Petrópolis Tupã City Primeira Hora Conesul Notícias Correio de Carajás Jornal da Nova Cassilândia Notícias Alta Pressão Online Tereré News TNH1 Jornal Joseense News Acontece Pará Jornalismo 24 Horas A Folha do Médio Norte Portal de Finanças Jornal Roraima Hoje Sinal Verde Real Deodorense Rede Clipex NewsGO O Dia Mais Paraguacity Chapecó Online Portal Rede Notícias Portal Lapada Lapada Ariquemes Folha de Dourados online Repórter PB Falando de Gestão Amazonas Total Portal Stylo Guará Notícias Guia Itaúna Portal Amirt Ciclo Vivo Terra UNICAMP - Universidade Estadual de Campinas Visão Cidade Net Connect Notícias O Presente online Midia News Campo Grande Plantão Angélica Portal do Litoral PB Bem Mais Brasília Blog do José Duarte Lima Colniza Notícias VoxMS Jornal do Comércio (Matão, SP) online Tá na Área Rádio Imprensa FM A Semana News Amazônia Jornal O Mossoroense Jornal Correio do Norte (PR) online Paraiba.com.br Diário da Amazônia Metropolitano Agora MS Hoje Amambai Notícias Innaldo Sardinha Anahp - Associação Nacional de Hospitais Privados Diário de Aparecida (GO) Carta Campinas A Folha Notícias (MT) Os Cabeças da Notícia Metropóles Midia News Mundo Positivo O Verídico Portal do Governo do Estado de São Paulo Conexão Boas Notícias Bonde Dourados Agora Portal GRNews Cassilândia Notícias América Economía - Cluster Salud (Chile) Zé Dudu Portal Correio Solânea Online Panorama Farmacêutico LD - Ligação Direta Belém online Diário Online LACI Laboratório TV Jaqueira O Território Notícia Positiva (EUA) Política News Ponto de Vista Portal Saúde Agora Sabino Sonorização São Miguel para Todos Transparência MT Blog da Sindy Santos Rádio Itatiaia Juruá Online Visão Notícias Visão Popular Banzeiro Rádio Sociedade Gorutubana 1380 AM Rádio Cidade de Vitória Mundial Pirapora News Blog Maringá Você Meu Mundo Digital Jornal Aurora Empresas & Negócios online Sala de Notícias Studio Livre 98,5 FM (Rio Grande, RS) Rondônia Direta Click Xinguara Tudo Tudo Gazeta Minas a informação direta TV Pontual ITimes.news Ivi Hoje MT Alerta Notícia Todo Dia Portal Mangabeira Rádio Rio de Janeiro Câmara Municipal de Camaçari Conjunto Ceará Revista Analytica online Revista Amazônia Belezas da Vida Alta Paulista News Cidades na Net TV Caeté Portal do Holanda Veja aqui MS Farmacêutico Márcio Antoniassi GPS da Notícia O Rondoniense Gazeta de Varginha online Jornal Extra de Alagoas online Jornal Floripa Edição MS Portal AZ Cariri em Ação DHoje Interior online Miradouro Notícias A Voz do Xingu VinTV Portal Hora 1 News Amplitude News Portal Tailândia (PA) Paraíba Master Esperança FM (CE) Diopuava - Diocese de Guarapuava Consórcio Guaicurus News Founded (África do Sul) TV Assembleia - Assembleia Legislativa do Piauí (Alepi) O Âncora Saúde & Estilo Edição MS Giro nas Geraes Portal 22 Plantão do MS Correio Capixaba online Portal ES Ubaense Brasil Agora News Pernambuco.com Balaio de Notícia Repórter Especial Diário de Canoas online Jornal Vale dos Sinos Jornal de Gramado online Jornal Informal MSN (Canadá) Destaque BA Na Mídia MS Portal Angélica Click Sergipe Rádio Cultura 670 A Noticia Portal Fiocruz